



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Public Declaration of Interests and Confidentiality Undertaking of
European Medicines Agency (EMA),
Scientific Committee members and experts

Public declaration of interests

I, PERE GINÈS

Organisation/Company: HOSPITAL CLÍNIC DE BARCELONA, SPAIN

Country: Spain

do hereby declare on my honour that, to the best of my knowledge, the only direct or indirect interests I have in the pharmaceutical industry are those listed below:

2.1 Employment

No interest declared

2.2 Consultancy

Period	Company	Products	Therapeutic Indication
12/2021-12/2021	Behring	HUMAN ALBUMIN	COMPLICATIONS OF CIRRHOSIS
10/2020-10/2021	Rallybio	NO SPECIFIC PRODUCT, JUST EXPLORATION OF LANDSCAPE	HEPATORENAL SYNDROME
04/2020-04/2021	MALLINCKRODT	MNK 6106 L-ORNITHINE PHENYLACETATE	HEPATIC ENCEPHALOPATHY
03/2019-05/2019	GRIFOLS SA	HUMAN ALBUMIN	COMPLICATIONS OF CIRRHOSIS

2.3 Strategic advisory role

No interest declared

2.4 Financial interests

Classified as public by the European Medicines Agency

2

No interest declared

2.5 Principal investigator

No interest declared

2.6 Investigator

No Interest Declared

2.7 Grant / Funding to organisation /institution

Company	Subject Matter
GRIFOLS SA	ALBUMIN FOR MANAGEMENT OF HYPONATREMIA IN CIRRHOSIS
GILEAD SCIENCES	FUNDING SUPPORT FOR SCREENING FOR LIVER DISEASES
GILEAD SCIENCES	EVALUATION OF LIVER FIBROSIS IN PATIENTS WITH TYPE-2 DIABETES

2.8 Close family member interest

No interest declared

2.9 Repurposing of a medicinal product

No interest declared

2.10 Any other interests or facts

I'm Principal Investigator of a project funded by the H2020 program that evaluates the usefulness of simvastatin and rifaximin in the prevention of the development of Acute-on-chronic liver failure and other complications of cirrhosis (the LIVERHOPE project). The consortium includes the pharma company Alfa-Sigma which produces rifaximin in Europe.

I was investigator or PI of a number of independent investigator-initiated studies funded with public funds starting more than 20 years ago with different drugs for the treatment of hepatorenal syndrome. Drugs evaluated included ornipressin, noradrenaline, dopamine, misoprostol, and terlipressin.

I also participated in a number of independent investigator-initiated studies funded with public funds, starting more than 35 years ago, evaluating the efficacy of albumin in the prevention/treatment of complications of cirrhosis.

2.11 Committee for Advanced Therapies (CAT) member or alternate

Not a CAT member or alternate

CONFIDENTIALITY UNDERTAKING

Classified as public by the European Medicines Agency

In view of the following definitions:

"EMA Activities" encompass any meeting (including meeting preparation and follow-up, associated discussion or any other related activity) of the European Medicines Agency's Management Board, Committees, Working Parties, Expert Groups, or any other such meeting; work as an expert on assessments; work as an expert on guidance development.

"Confidential Information" means all information, facts, data and any other matters of which I acquire knowledge, either directly or indirectly, as a result of my EMA Activities.

"Confidential Documents" mean all drafts, preparatory information, documents and any other material, together with any information contained therein, to which I have access, either directly or indirectly, as a result of my participation in EMA Activities. Furthermore, any records or notes made by me relating to Confidential Information or Confidential Documents shall be treated as Confidential Documents.

I understand that I may be invited to participate either directly or indirectly in certain EMA activities and hereby undertake:

- To treat all Confidential Information and Confidential Documents under conditions of strict confidentiality as long as the information or document has not been made public/is not in the public domain.
- Not to disclose (or authorise any other person to disclose) in any way to any third party any Confidential Information or Confidential Document.
- Not to use (or authorise any other person to use) any Confidential Information or Confidential Document other than for the purposes of my work in connection with EMA activities.
- To dispose of Confidential Documents as confidential material as soon as I have no further use for them.
- When expressing views to clearly indicate that the views are my own if acting in my own capacity or those of the EMA, Committee, Working Party, Expert Group or other group if acting on behalf that group.
- Not to disclose any commercially confidential information.

This undertaking shall not be limited in time, but shall not apply to any document or information that I can reasonably prove was known to me before the date of this undertaking or which becomes public knowledge other than as a result of a breach of any of the above undertakings.

I confirm the information declared on this form is accurate to the best of my knowledge and I acknowledge that my information will be stored electronically and published on the EMA website.

Full Name:	Pere Ginès Gibert
Date:	2022-05-13

For Definitions of activities etc, refer to Policy on Handling of competing interests / Electronic DOI template